Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a ?subsidiary of Roivant Sciences, and Arbutus ?Biopharma up to $2.25 billion to settle a ?long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday. Under the deal, ?Moderna will ?pay $950 million upfront in July 2026, with an additional $1.3 billion ?that depends on the outcome of a separate legal appeal. In extended trading, ?Moderna's shares ?jumped more than ?10%, Arbutus rose ?11%, while Roivant was up about 1%. The deal resolves all U.S. and international legal actions accusing Moderna of using lipid nanoparticle, or LNP, a delivery ?technology owned by ?Genevant and Arbutus, without ?permission in ?its COVID-19 shot, Spikevax. LNP technology ?acts as a tiny ?protective shell ?that helps fragile mRNA molecules reach human cells intact, a key ?component that ?allows mRNA vaccines to work. (Reporting ?by Kamal Choudhury in Bengaluru; Editing ?by Al
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance]Yahoo! Finance
- Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance Canada]Yahoo! Finance Canada
- Roivant Sciences (ROIV) had its price target raised by HC Wainwright from $33.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 3/3/26 - Form 8-K
- 3/3/26 - Form 8-K
- 2/24/26 - Form 4
- ROIV's page on the SEC website